Journal: Nucleic Acids Research
Article Title: Chromatin context-dependent effects of epigenetic drugs on CRISPR-Cas9 editing
doi: 10.1093/nar/gkae570
Figure Lengend Snippet: Overview of the reporter system and screen data. ( A ) Heatmap of the chromatin landscape at the integration sites of the integrated pathway reporters (IPRs) in K562 clone #5 used in this study. Z -scores of 25 chromatin features are indicated for all 19 IPRs. Chromatin features are colored by their type, and IPRs are clustered into chromatin groups based on the chromatin features. IPRs in bold are the two example IPRs depicted in B. Adapted from . ( B ) Left panel: genomic locations of the IPRs, colored by their associated chromatin group. Right panel: indel frequency distributions (in the absence of drug treatment) of two representative IPRs, one in euchromatin (IPR5), and one in heterochromatin (IPR7). ( C ) Number of drugs per target group in the screen. HDAC = histone deacetylase, JAK = Janus kinase, AurK = aurora kinase, PARP = poly (ADP-ribose) polymerase, ERD = epigenetic reader domain, HMT = histone methyltransferase, PIM = proviral integration site for moloney murine leukemia virus kinase, HDM = histone demethylase, DNMT = DNA methyltransferase, HAT = histone acetyltransferase and HIF = hypoxia inducible factor. ( D ) Schematic overview of the experimental layout and the readouts of the drug screen.
Article Snippet: For the drug addition, we combined two 96-well epigenetic drug screening libraries from two commercially available libraries from Selleck Chemicals and Enzo Life Sciences (for list of drugs see ).
Techniques: Histone Deacetylase Assay, Virus